首都医科大学附属北京友谊医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma12 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma51 篇牵头论文牵头 1 项开放试验
- 胃癌Stomach cancer45 篇牵头论文牵头 7 项开放试验
- 肝母细胞瘤Hepatoblastoma1 篇牵头论文
- 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
- 骨肉瘤Osteosarcoma2 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour2 篇牵头论文
- 神经母细胞瘤Neuroblastoma47 篇牵头论文
- 尤文肉瘤Ewing sarcoma1 篇牵头论文
- 多发性骨髓瘤Multiple myeloma1 篇牵头论文
- 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis52 篇牵头论文牵头 3 项开放试验
- 血友病 AHaemophilia A0 篇牵头论文
- 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura0 篇牵头论文
- IgG4相关性疾病IgG4-related disease12 篇牵头论文
- 重症肌无力Myasthenia gravis1 篇牵头论文
- 肝豆状核变性Wilson disease4 篇牵头论文牵头 1 项开放试验
- 胆道闭锁Biliary atresia4 篇牵头论文
- 大动脉炎Takayasu arteritis2 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
- 庞贝病Pompe disease1 篇牵头论文
- 白塞病Behçet disease1 篇牵头论文
- IgA 肾病IgA nephropathy0 篇牵头论文
- 戈谢病Gaucher disease2 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis12 篇牵头论文牵头 1 项开放试验
- 原发性硬化性胆管炎Primary sclerosing cholangitis4 篇牵头论文
- 先天性巨结肠Hirschsprung disease0 篇牵头论文
未列出的收录疾病:鼻咽癌、脊索瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、β 地中海贫血、非典型溶血性尿毒症综合征、范可尼贫血、视神经脊髓炎谱系疾病、烟雾病、抗 NMDA 受体脑炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、杜氏肌营养不良、Alport 综合征、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.4%。
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 13 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- 分期
- I期
- 开始
- 2022-10
- 登记号
- NCT05208762
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文12
- Unraveling the tumor microenvironment of esophageal squamous cell carcinoma through single-cell sequencing: A comprehensive review.
- Predicting pathological response of resectable esophageal squamous cell carcinoma to neoadjuvant anti-PD-1 with chemotherapy using serum inflammation indexes.
- Lysophosphatidic acid promotes ESCC progression by increasing the level of CCL2 secreted by esophageal epithelial cells.
- Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis.
- Endoscopic Submucosal Dissection for Hypervascularized Esophageal Squamous Cell Carcinoma in Decompensated Cirrhosis With Esophageal Varices and Scars.
- Expression and Significance of N-myc downstream regulated gene 2 in the process of Esophageal Squamous Cell Carcinogenesis.
- Clinical characteristics, prognostic factors, and survival trends in esophageal neuroendocrine carcinomas: A population-based study.
- Porphyromonas gingivalis secretion leads to dysplasia of normal esophageal epithelial cells via the Sonic hedgehog pathway.
- Circ_0001821 Affects Proliferation and the Cell Cycle in Esophageal Squamous Cell Carcinoma by Elevating BTRC-Mediated IKBA Ubiquitination.
- Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature.
- Comorbid early esophageal cancer and Gongylonema pulchrum infection: a case report.
- Lysophosphatidic acid mediated PI3K/Akt activation contributed to esophageal squamous cell cancer progression.
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
PubMed 以外找到的论文(未计入)2
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 51 篇,占 0.4%。
北京有 17 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 即将招募HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
- 分期
- 未注明
- 开始
- 2026-08
- 登记号
- NCT07780357
年龄 18 岁 至 未注明(登记的条件)
牵头:首都医科大学附属北京友谊医院北京
- 正在招募Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- 分期
- III期
- 开始
- 2023-05
- 登记号
- NCT05862337
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙
- 正在招募A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- 分期
- I期
- 开始
- 2022-10
- 登记号
- NCT05208762
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文51
- Unstable Recompensation: An Intermediate Subtype in Patients With HBV-Related Decompensated Cirrhosis.
- Role of the nucleotide excision repair function of CETN2 in the inhibition of the sensitivity of hepatocellular carcinoma cells to oxaliplatin.
- Predicting Treatment Response to Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients using a Deep Learning-based Approach.
- Novel immune-related prognostic models for patients with hepatocellular carcinoma after curative resection.
- Stage-Specific Transcriptome Landscape of Hepatocellular Carcinoma: Insights From Super and Poor Survivors With Prognostic Signature Identification.
- Monitoring Sorafenib Resistance and Efficacy in Hepatocellular Carcinoma Using [18F]Alfatide II and [18F]Fluorodeoxyglucose Positron Emission Tomography.
- Novel role of general transcript factor IIH subunit 2 (GTF2H2) in the development and sex disparity of hepatocellular carcinoma.
- Deep learning for hepatocellular carcinoma recurrence before and after liver transplantation: a multicenter cohort study.
- Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis.
- Preoperative prediction power of radiomics and non-radiomics methods based on MRI for early recurrence in hepatocellular carcinoma: a systemic review and meta-analysis.
- Deep learning-based arterial subtraction images improve the detection of LR-TR algorithm for viable HCC on extracellular agents-enhanced MRI.
- The timing phase affected the inconsistency of APHE subtypes of liver observations in patients at risk for HCC on the multi-hepatic arterial phase imaging.
- The Diagnostic Accuracy Between Radiomics Model and Non-radiomics Model for Preoperative of Microvascular Invasion of Solitary Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
- Inter-reader agreement of LI-RADS treatment response algorithm among three readers with different seniorities for hepatocellular carcinoma after locoregional therapy.
- Optimizing LI-RADS: ancillary features screened from LR-3/4 categories can improve the diagnosis of HCC on MRI.
- Preoperative evaluation of microvascular invasion in hepatocellular carcinoma with a radiological feature-based nomogram: a bi-centre study.
- Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.
- Risk of transplant rejection associated with ICIs prior to liver transplantation in HCC: A multicenter retrospective study.
- Changing spectrum and mortality disparities of etiology of liver cirrhosis in Beijing, China.
- Ablative Treatments and Surgery for Early-Stage Hepatocellular Carcinoma: A Network Meta-Analysis.
- MRI-based radiomics model and nomogram for predicting the outcome of locoregional treatment in patients with hepatocellular carcinoma.
- Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.
- The clinical management of hepatocellular carcinoma in China: Progress and challenges.
- Comparison of quantitative volumetric analysis and linear measurement for predicting the survival of Barcelona Clinic Liver Cancer 0- and A stage hepatocellular carcinoma after radiofrequency ablation.
- The role of 18F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.
- Recompensation in treatment-naïve HBV-related decompensated cirrhosis: a 5-year multi-center observational study comparing patients with ascites and bleeding.
- Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis.
- Two-year free of complications during antiviral therapy predicts stable re-compensation in immediate-treatment HBV-related decompensated cirrhosis.
- Platelet membrane-derived microparticles may be biomarkers in patients with hepatocellular carcinoma and can promote the invasion and metastasis of hepatoma carcinoma cells.
- Histological assessment based on liver biopsy: the value and challenges in NASH drug development.
- Diagnostic performance of imaging features in the HBP of gadoxetate disodium-enhanced MRI for microvascular invasion in hepatocellular carcinoma: a meta-analysis.
- High-throughput circular RNA sequencing reveals the profiles of circular RNA in non-cirrhotic hepatocellular carcinoma.
- Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features.
- CT-based skeletal muscle loss for predicting poor survival in patients with hepatocellular carcinoma experiencing curative hepatectomy plus adjuvant transarterial chemoembolization: a preliminary retrospective study.
- Systematic review and meta-analysis: impact of anti-viral therapy on portal hypertensive complications in HBV patients with advanced chronic liver disease.
- Roles of small extracellular vesicles in the development, diagnosis and possible treatment strategies for hepatocellular carcinoma (Review).
- Clinical evidence of outcomes following liver transplantation in patients with nonalcoholic steatohepatitis: An updated meta-analysis and systematic review.
- Predictive value of hepatic venous pressure gradient and efficacy and significance of early PTVE for gastrointestinal bleeding after TACE for liver cancer.
- Predictors of mid-term survival after liver transplantation in patients with NAFLD cirrhosis.
- Predicting hepatocellular carcinoma early recurrence after ablation based on magnetic resonance imaging radiomics nomogram.
- Downregulation of HULC Induces Ferroptosis in Hepatocellular Carcinoma via Targeting of the miR-3200-5p/ATF4 Axis.
- Baicalin suppresses the progression of Type 2 diabetes-induced liver tumor through regulating METTL3/m6A/HKDC1 axis and downstream p-JAK2/STAT1/clevaged Capase3 pathway.
- Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints.
- Exosome-derived GTF2H2 from Huh7 cells can inhibit endothelial cell viability, migration, tube formation, and permeability.
- Role of tight junction-associated MARVEL protein marvelD3 in migration and epithelial-mesenchymal transition of hepatocellular carcinoma.
- Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation.
- Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis.
- Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy.
- Does Training in LI-RADS Version 2018 Improve Readers' Agreement with the Expert Consensus and Inter-reader Agreement in MRI Interpretation?
- Magnetic resonance radiomics signatures for predicting poorly differentiated hepatocellular carcinoma: A SQUIRE-compliant study.
- Apoptosis-induced translocation of centromere protein F in its corresponding autoantibody production in hepatocellular carcinoma.
中文论文(未计入)5
- [Application and prospects of magnetic resonance imaging techniques in the diagnosis and evaluation of hepatocellular carcinoma].
- [Construction of a stable centromere protein F overexpression cell model of hepatocellular carcinoma using CRISPR activation system].
- [Expression and Clinical Significance of ATP Citrate Lyase in Hepatocellular Carcinoma].
- [Low-level viremia-induced liver fibrosis and hepatocellular carcinoma in chronic hepatitis B].
- [Correlation among age, sex, and liver diseases-related mortality risk in patients with hepatitis B virus-related liver cirrhosis].
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
- HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
- Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 45 篇,占 0.5%。
北京有 15 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 11
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy
- 分期
- 不分期
- 开始
- 2026-03
- 登记号
- NCT07441850
年龄 18 岁 至 70 岁(登记的条件)
牵头:首都医科大学附属北京友谊医院北京
- 正在招募Retrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical Dataset
- 分期
- 未注明
- 开始
- 2026-05
- 登记号
- NCT07747688
年龄 18 岁 至 90 岁(登记的条件)
牵头:首都医科大学附属北京友谊医院北京
- 正在招募Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer
- 分期
- 不分期
- 开始
- 2026-08
- 登记号
- NCT07835087
年龄 18 岁 至 80 岁(登记的条件)
牵头:首都医科大学附属北京友谊医院北京
- 正在招募Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
- 分期
- II期
- 开始
- 2025-11
- 登记号
- NCT07315854
年龄 18 岁 至 80 岁(登记的条件)
牵头:首都医科大学附属北京友谊医院北京
- 正在招募Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
- 分期
- II期
- 开始
- 2025-05
- 登记号
- NCT07353684
年龄 18 岁 至 75 岁(登记的条件)
牵头:首都医科大学附属北京友谊医院北京
- 正在招募Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer(IDEAL Stage 2b)
- 分期
- 不分期
- 开始
- 2024-02
- 登记号
- NCT06788548
年龄 18 岁 至 80 岁(登记的条件)
牵头:首都医科大学附属北京友谊医院北京
- 正在招募Validating a Medical AI Fine-Tuning Platform for Major Diseases
- 分期
- 未注明
- 开始
- 2024-11
- 登记号
- NCT07795645
年龄 18 岁 至 未注明(登记的条件)
牵头:首都医科大学附属北京友谊医院北京
- 正在招募Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- 分期
- III期
- 开始
- 2026-04
- 登记号
- NCT07385703
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- 分期
- III期
- 开始
- 2026-09
- 登记号
- NCT07700979
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、北京、广州
- 正在招募Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- 分期
- 未注明
- 开始
- 2025-02
- 登记号
- NCT06846996
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春
- 正在招募A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- 分期
- I期
- 开始
- 2022-10
- 登记号
- NCT05208762
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文45
- Comparison on the reflux and nutritional status of different reconstruction methods after laparoscopic proximal gastrectomy: a systematic review and network meta-analysis.
- Clinicopathological characteristics of 30 cases of pyloric gland adenoma: a single center case series.
- Lectin-affinity glycosylation pattern analysis of plasma extracellular vesicles: An all-in-one clinical assessment for gastric cancer diagnosis and treatment.
- Fusobacterium nucleatum drives gastric cancer metastasis via Gbp-CypA-NF-κB-mediated CXCL8 crosstalk between tumor cells and mast cells.
- Helicobacter pylori CagA promotes gastric cancer immune escape by upregulating SQLE.
- Functions and Clinical Applications of Exosomes in Gastric Cancer.
- Generation of surgical reports for lymph node dissection during laparoscopic gastric cancer surgery based on artificial intelligence.
- Efficient Metabolomics Profiling from Plasma Extracellular Vesicles Enables Accurate Diagnosis of Early Gastric Cancer.
- Prognostic implications of the interaction between intratumoral microbiome and immune response in gastric cancer.
- Incidental Finding of a Primary Polypoid Low-Grade B-Cell Gastric Lymphoma Managed with Chemotherapy.
- Development and validation of a nomogram incorporating dietary factors for predicting Helicobacter pylori-negative early gastric cancer risk.
- Clinicopathologic and endoscopic characteristics of ten patients with gastric hamartomatous inverted polyp: a single center case series.
- Chinese national clinical practice guidelines on the prevention, diagnosis, and treatment of early gastric cancer.
- Perioperative chemotherapy versus adjuvant chemotherapy in patients with resectable gastric cancer: A systematic review with meta-analysis.
- Risk factors and a nomogram for predicting local recurrence in adult patients with early gastric cancer after endoscopic submucosal dissection.
- Investigating biomechanical alterations and emptying patterns after various gastrojejunostomy strategy.
- A nomogram for predicting survival based on hemoglobin A1c and circulating tumor cells in advanced gastric cancer patients receiving immunotherapy.
- Artificial intelligence for automatic surgical phase recognition of laparoscopic gastrectomy in gastric cancer.
- Assessment of risk factors of lymph node metastasis and prognosis of Siewert II/III adenocarcinoma of esophagogastric junction: A retrospective study.
- Helicobacter pylori promotes gastric fibroblast proliferation and migration by expulsing exosomal miR-124-3p.
- LncRNA CASC19 promotes gastric cancer progression through preventing CREB1 protein ubiquitin/proteasome-dependent degradation.
- LncRNA CASC19: a novel oncogene involved in human cancer.
- Efficacy and safety of combination chemotherapy regimens containing taxanes for first-line treatment in advanced gastric cancer.
- Both extracellular vesicles from helicobacter pylori-infected cells and helicobacter pylori outer membrane vesicles are involved in gastric/extragastric diseases.
- TRIM28 suppresses cancer stem-like characteristics in gastric cancer cells through Wnt/β-catenin signaling pathways.
- Anthracycline chemicals with anthracyclinone structure exert antitumor effects by inhibiting angiogenesis and lymphangiogenesis in a xenografted gastric tumor model.
- Predictive performance of radiomics for peritoneal metastasis in patients with gastric cancer: a meta-analysis and radiomics quality assessment.
- Identification and evaluation of novel serum autoantibody biomarkers for early diagnosis of gastric cancer and precancerous lesion.
- Safety and efficacy of augmented-rectangle technique versus delta-shaped anastomosis for treating gastric cancer in total laparoscopic distal gastrectomy.
- Safety and efficacy of laparoscopic proximal gastrectomy with SOFY versus laparoscopic total gastrectomy with Roux-en-Y for treating cT1-2 Siewert II/III adenocarcinoma of the esophagogastric junction: a single-center prospective cohort stu
- Circulating Tumor Cells as Diagnostic Markers of Early Gastric Cancer and Gastric Precancerous Lesions.
- Endoscopic and clinicopathologic features of early gastric signet ring cell carcinoma ≤20 mm: a retrospective observational study.
- Comparison of endoscopic submucosal dissection outcomes between early gastric cardiac and non-cardiac cancers: a retrospective single-center study.
- Autoimmune gastritis with a gastric hamartomatous inverted polyp and two hyperplastic polyps: a case report.
- External validation of the BEST-J score and a new risk prediction model for ESD delayed bleeding in patients with early gastric cancer.
- MiR-1298-5p level downregulation induced by Helicobacter pylori infection inhibits autophagy and promotes gastric cancer development by targeting MAP2K6.
- Deep biopsy via endoscopic submucosal dissection for primary gastric amyloidosis.
- Immune Profiling in Gastric Cancer Reveals the Dynamic Landscape of Immune Signature Underlying Tumor Progression.
- Gastric lesions in patients with autoimmune metaplastic atrophic gastritis: a retrospective study in a single center.
- Short-term outcomes of three rare cases of intramucosal Epstein-Barr virus-associated gastric cancer treated with endoscopic submucosal dissection.
- Leukemia inhibitory factor promotes gastric cancer cell proliferation, migration, and invasion via the LIFR-Hippo-YAP pathway.
- The Significance of Exosomal RNAs in the Development, Diagnosis, and Treatment of Gastric Cancer.
- IL-15-induced lymphocytes as adjuvant cellular immunotherapy for gastric cancer.
- Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinoma.
- Asporin represses gastric cancer apoptosis via activating LEF1-mediated gene transcription independent of β-catenin.
中文论文(未计入)3
- [Application research of endoscopic-laparoscopic regional gastric resection combined with sentinel lymph node basin dissection in patients with early gastric cancer].
- [Pathological features of early gastric cancer and its background mucosa after eradication of Helicobacter pylori and their implications for biopsy diagnosis].
- [Analysis of the clinical confusion and controversy of esophagogastric junction tumor from basic anatomy].
它在 ClinicalTrials.gov 上的全部试验(任何状态)25
- Retrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical Dataset
- Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer
- Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy
- Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
- Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
- Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer(IDEAL Stage 2b)
- Validating a Medical AI Fine-Tuning Platform for Major Diseases
- Exosome-based Liquid Biopsies for Upper Gastrointestinal Cancers Diagnosis
- Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
- Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis
- Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer
- Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer
- Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer
- Expanded Indications of Endoscopic Submucosal Dissection for Early Gastric Cancer in China
- A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer
- Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection for Early Gastric Cancer
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer
癌症
肝母细胞瘤
Hepatoblastoma2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 9 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 10 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.09%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 48 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
牵头的论文2
- Incidental detection of Ewing sarcoma in the thoracic spinal cord by 18F-FDG PET/CT in a pediatric patient with cerebral infarction.
- Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study.
早期论文(2016–2020 年)4
- LOXL1-AS1 predicts poor prognosis and promotes cell proliferation, migration, and invasion in osteosarcoma.
- Overexpression of FER1L4 promotes the apoptosis and suppresses epithelial-mesenchymal transition and stemness markers via activating PI3K/AKT signaling pathway in osteosarcoma cells.
- Systematic meta-analysis of genetic variants associated with osteosarcoma susceptibility.
- Meta-analysis of clinical significance of p53 protein expression in patients with osteosarcoma.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 23 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
这些数字背后的记录
牵头的论文2
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 47 篇,占 4.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 24 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
这些数字背后的记录
牵头的论文47
- Solitary Humeral Metastasis in the Absence of Detectable Primary Neuroblastoma on Triple-tracer Imaging With 18F-FDG, 123I-MIBG, and 68Ga-DOTATATE.
- False Positive of 123 I-MIBG Caused by Ectopic Thymic Rebound Hyperplasia in a Pediatric Neuroblastoma.
- Unusual Initial Presentation of Epileptic Seizures in a Pediatric Patient With Neuroblastoma Detected by 18 F-FDG PET/CT Imaging.
- 18 F-FDG PET/CT Demonstrates Left Adrenal Neuroblastoma in a Pediatric Patient With Beckwith-Wiedemann Syndrome.
- 68 Ga-DOTATATE Uptake in Pulmonary Lymphangitic Carcinomatosis: A Rare Form of Metastasis in Pediatric Neuroblastoma.
- Comparison of Iodine-123 Metaiodobenzylguanidine scintigraphy with SPECT/CT and Fluorine-18-aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide PET/CT in recurrent High-risk neuroblastoma after complete remission.
- 18F-FDG PET/CT volumetric parameter predicts prognosis for neuroblastoma with MYCN gain.
- Application of modified Curie and SIOPEN skeleton scoring systems in 18F-AlF-NOTA-octreotide PET/CT for neuroblastoma.
- The baseline 18F-FDG PET/CT imaging features in pediatric patients with congenital neuroblastoma.
- The prognostic significance of semi-quantitative metabolic parameters and tumoral metabolic activity based on 123I-MIBG SPECT/CT in pretreatment neuroblastoma patients.
- The Role of 18 F-AlF-NOTA-Octreotide PET/CT in the Evaluation of Central Nervous System Metastases in Neuroblastoma : A Preliminary Study.
- Completely Negative 123 I-MIBG SPECT/CT, but Strong Positive 68 Ga-DOTATATE PET/CT of Multiple Metastases in a Neuroblastoma Patient.
- Recurrent Solitary Pleural Metastasis Originating From Neuroblastoma as Demonstrated by 123I-MIBG Scan.
- Pseudoprogression on 68Ga-DOTATATE PET/CT in a Pediatric Patient With Neuroblastoma.
- Positive 18 F-FDG PET/CT and Negative 123 I-MIBG SPECT/CT Imaging in an Unusual Diaphragmatic Metastasis From Ganglioneuroblastoma.
- Incidental Detection of Choroid Plexus Metastasis From Neuroblastoma Demonstrated by 68 Ga-DOTATATE PET/CT.
- False-Positive Uptake of 123 I-MIBG in the Basal Ganglion in a Pediatric Neuroblastoma Patient.
- 68 Ga-DOTATATE PET/CT Demonstrated More Lesions of Leptomeningeal Metastases Compared With 123 I-MIBG SPECT/CT in a Pediatric Neuroblastoma Patient.
- Concurrent Intracranial and Spinal Dural Metastases Demonstrated by 68 Ga-DOTATATE PET/CT With Negative 123 I-MIBG SPECT/CT in a Pediatric Neuroblastoma Patient.
- A False-Negative 123 I-MIBG SPECT/CT With True-Positive 68 Ga-DOTATATE PET/CT in a Patient With Neuroblastoma Following 177 Lu-DOTATATE Therapy.
- Predictive value of multiparametric diagnostic model based on 2-[18F]-fluoro-D-glucose (2-[18F]-FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in differentiating between neuroblastoma and ganglioneurobla
- Radiomics analysis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography for differentiating the histological classification of peripheral neuroblastic tumours.
- A head-to-head prospective comparative analysis of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT/CT in central nervous system metastases of neuroblastoma and ganglioneuroblastoma.
- GD2-targeted theranostics of neuroblastoma with [64Cu]Cu/[177Lu]Lu-hu3F8.
- Radiomics-based prediction of pathological subtypes in peripheral neuroblastic tumors using 123I-MIBG SPECT/CT imaging: an observational study.
- Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas.
- Differentiation of early relapse and late relapse in intermediate- and high-risk neuroblastoma with an 18F-FDG PET/CT-based radiomics nomogram.
- Prognostic Value of Metabolic Parameters and Textural Features in Pretreatment 18F-FDG PET/CT of Primary Lesions for Pediatric Patients with Neuroblastoma.
- 18F-FDG PET/CT-Based Radiomics Nomogram for Prediction of Bone Marrow Involvement in Pediatric Neuroblastoma: A Two-Center Study.
- Whole-tumoral metabolic heterogeneity in 18F-FDG PET/CT is a novel prognostic marker for neuroblastoma.
- Jaundice as a Rare Presentation of Neuroblastoma in a Pediatric Patient.
- Coexistence of Langerhans Cell Histiocytosis and Ganglioneuroblastoma Revealed by 18 F-FDG PET/CT in a Pediatric Patient.
- Solitary Dural Metastasis From Neuroblastoma Detected by 123 I-MIBG SPECT/CT.
- Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging in pediatric opsoclonus myoclonus ataxia syndrome presenting with neuroblastoma.
- Predicting event-free survival after induction of remission in high-risk pediatric neuroblastoma: combining 123I-MIBG SPECT-CT radiomics and clinical factors.
- An Optimal Radiomics Nomogram Based on 18F-FDG PET/CT for Identifying Event-Free Survival in Pediatric Neuroblastoma.
- Axial Skeleton Radiomics of 18F-FDG PET/CT: Impact on Event-Free Survival Prediction in High-Risk Pediatric Neuroblastoma.
- Diagnostic Value of 18F-FDG PET/CT-Based Radiomics Nomogram in Bone Marrow Involvement of Pediatric Neuroblastoma.
- Leptomeningeal Metastasis From Neuroblastoma Revealed by 123 I-MIBG SPECT/CT.
- Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification.
- Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma.
- Clinical parameters combined with radiomics features of PET/CT can predict recurrence in patients with high-risk pediatric neuroblastoma.
- The prognostic value of 18F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients.
- MIBG Uptake in Pancreas as a Normal Variant.
- The Diagnostic Value of 18F-FDG PET/CT Bone Marrow Uptake Pattern in Detecting Bone Marrow Involvement in Pediatric Neuroblastoma Patients.
- An 18F-FDG PET/CT radiomics nomogram for differentiation of high-risk and non-high-risk patients of the International Neuroblastoma Risk Group Staging System.
- Diagnostic Value of Seven Different Imaging Modalities for Patients with Neuroblastic Tumors: A Network Meta-Analysis.
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 17 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.06%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 15 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。
血液疾病
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 52 篇,占 13.0%。
北京有 11 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下
这家医院参与的开放试验 4
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Prospective Single-Arm Clinical Trial of GO Regimen for HLH.
- 分期
- II/III期
- 开始
- 2025-06
- 登记号
- NCT07339345
年龄 14 岁 至 70 岁(登记的条件)
牵头:首都医科大学附属北京友谊医院北京
- 即将招募Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections
- 分期
- 不分期
- 开始
- 2023-08
- 登记号
- NCT05988177
年龄 18 岁 至 未注明(登记的条件)
牵头:首都医科大学附属北京友谊医院北京
- 即将招募Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
- 分期
- 未注明
- 开始
- 2023-12
- 登记号
- NCT06131489
年龄 18 岁 至 未注明(登记的条件)
牵头:首都医科大学附属北京友谊医院北京
- 正在招募A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- 分期
- III期
- 开始
- 2025-11
- 登记号
- NCT07208058
年龄 16 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南昌、广州、杭州、武汉、沈阳、石家庄、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文52
- Monocyte/macrophages may exert prominent roles in macrophage activation syndrome.
- Clinical and prognostic significance of whole blood Epstein-Barr virus DNA in patients with primary hemophagocytic lymphohistiocytosis: a retrospective observational study from China.
- CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic lymphohistiocytosis treated with RED (ruxolitinib, emapalumab and dexamethasone).
- Epstein-Barr virus infection and prognosis in haemophagocytic lymphohistiocytosis patients with underlying rheumatic diseases: a single-centre retrospective study.
- The effectiveness of etoposide-containing chemotherapy regimens in the initial treatment of Hemophagocytic Syndrome in pregnancy.
- Epstein-Barr virus infection plays a crucial role in triggering hemophagocytic lymphohistiocytosis in patients with X-linked inhibitor of apoptosis protein deficiency.
- Off-label use of recombinant activated factor VII in hemophagocytic lymphohistiocytosis patients with major bleeding.
- Exploring the Complexities of Liver Transplantation for Secondary Hemophagocytic Lymphohistiocytosis-Associated Acute Liver Failure.
- Characteristics of epilepsy associated with hemophagocytic lymphohistiocytosis.
- The effectiveness of the doxorubicin-etoposide-methylprednisolone regimen for adult HLH secondary to rheumatic disease.
- A convenient and practical index for predicting the induction response in adult patients with hemophagocytic lymphohistiocytosis: ferritin/platelet ratio.
- Haemophagocytic lymphohistiocytosis caused by GATA2 deficiency: a report on three patients.
- Transplantation in adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: yes or no?
- Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells.
- Enhancing diagnostic precision in EBV-related HLH: a multifaceted approach using 18F-FDG PET/CT and nomogram integration.
- Etiological stratification and prognostic assessment of haemophagocytic lymphohistiocytosis by machine learning on onco-mNGS data and clinical data.
- The efficacy and safety of chidamide in combination with etoposide and glucocorticoids for the treatment of hemophagocytic lymphohistiocytosis in adult patients: an open-label, single-center study.
- Acute kidney injury in critical care: complications of hemophagocytic lymphohistiocytosis.
- Beta 2-microglobulin is an independent risk marker of acute kidney injury in adult patients with hemophagocytic lymphohistiocytosis.
- Prognostic scoring system for pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis based on baseline characteristics: A multicenter retrospective study.
- Ocular Phenotypes in Patients With Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis in a Single Center Over 7 Years.
- Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients.
- Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives.
- Case Report: HAVCR2 mutation-associated Hemophagocytic lymphohistiocytosis.
- Serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation.
- Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study.
- The diagnostic importance of multiple cytokines in adult hemophagocytic lymphohistiocytosis.
- L-DEP regimen is effective as an initial therapy for adult EBV-HLH.
- Epstein-Barr virus central nervous system involvement in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
- Clinical characteristics and treatment of NK/T-cell lymphoma-associated HLH.
- Serum ferritin is a good indicator for predicting the efficacy of adult HLH induction therapy.
- Macrophage activation syndrome in adults: Characteristics, outcomes, and therapeutic effectiveness of etoposide-based regimen.
- The Outcome of Induction Therapy for EBV-Related Hemophagocytic Lymphohistiocytosis: A Model for Risk Stratification.
- Outcomes of allogeneic hematopoietic stem cell transplantation for primary hemophagocytic lymphohistiocytosis in adults.
- A Study on Early Death Prognosis Model in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis.
- Development and Validation of 18F-FDG PET/CT-Based Multivariable Clinical Prediction Models for the Identification of Malignancy-Associated Hemophagocytic Lymphohistiocytosis.
- Prognosis predicting value of semiquantitative parameters of visceral adipose tissue and subcutaneous adipose tissue of 18F-FDG PET/CT in newly diagnosed secondary hemophagocytic lymphohistiocytosis.
- Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial.
- Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis.
- Autologous Hematopoietic Stem Cell Transplantation for Patients with Lymphoma-Associated Hemophagocytic lymphohistiocytosis.
- Successful resolution of hemophagocytic lymphohistiocytosis during the chemotherapy course of acute myelocytic leukemia with ruxolitinib.
- Ruxolitinib treatment for bronchiolitis obliterans syndrome following hematopoietic stem cell transplant in a patient with primary hemophagocytic lymphohistiocytosis.
- Multiple-Organ Involvement in Familial Hemophagocytic Lymphohistiocytosis Type 2 Shown on FDG PET/CT.
- Clinical and laboratory signs of haemophagocytic lymphohistiocytosis associated with pandemic influenza A (H1N1) infection in patients needing extracorporeal membrane oxygenation: A retrospective observational study.
- Successful treatment of cytomegalovirus-induced hemophagocytic lymphohistiocytosis with ruxolitinib as a first-line treatment.
- Epstein-Barr virus infection is an important cause of hemophagocytic lymphohistiocytosis during chemotherapy for lymphoma.
- Hemophagocytic lymphohistiocytosis secondary to disseminated histoplasmosis in an immunocompetent patient.
- Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection.
- Non-EBV infection-associated hemophagocytic lymphohistiocytosis: a distinct subgroup where pathogen-directed therapy is essential and favorable outcomes are expected.
- The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis.
- Epidemiological investigation of hemophagocytic lymphohistiocytosis in China.
- Clinical and laboratory characteristics of hemophagocytic lymphohistiocytosis induced by Leishmania infantum infection.
中文论文(未计入)8
- [Clinical Characteristics Analysis of EBV-associated Hemophagocytic Lymphohistiocytosis Patients with Acute Kidney Injury].
- [Clinical and genetic mutation characteristics of patients with primary hemophagocytic lymphohistiocytosis and their impact on prognosis].
- [Characteristic and prognosis of patients with non-EBV infection-associated hemophagocytic lymphohistiocytosis].
- [Evaluation of CD107a and perforin expression detection in the diagnosis of primary hemophagocytic lymphohistiocytosis].
- [New era of accurate diagnosis of hemophagocytic lymphohistiocytosis].
- [Interpretation of Chinese expert consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with lymphoma (2022)].
- [Exhaustion of CD8+T Lymphocytes Plays a Critical Role in the Pathogenesis of Secondary Hemophagocytic Lymphohistiocytosis].
- [Clinical study on the effect of etoposide-containing induction regimen for adult-onset Still's disease associated hemophagocytic syndrome].
它在 ClinicalTrials.gov 上的全部试验(任何状态)29
- Prospective Single-Arm Clinical Trial of GO Regimen for HLH.
- Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections
- Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
- A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT
- Response Prediction in EBV-HLH Using Metabonomics Analysis
- L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
- Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH
- L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH
- Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients
- Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH
- Zanubrutinib for HLH
- Clinical Study of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-HLH After Allo-HSCT
- Rituximab Monotherapy for EBV-HLH and CAEBV
- PD-1 Antibody Improve Mixed Chimerism
- Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH
- DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH
- PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
- Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.
- Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis
- DEP-Ru Regimen as a Salvage Therapy for HLH
- Etoposide in the First-line Treatment of Adult EBV-HLH
- L-DEP as an Initial Treatment for EBV-HLH
- Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology
- L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis
- A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))
- Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
- Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome
- A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis(HLH)
PubMed 以外找到的论文(未计入)8
- Anakinra for hemophagocytic lymphohistiocytosis: A real-world, multicenter retrospective study on efficacy, safety, and response durability
- Clinical and genetic features of primary hemophagocytic lymphohistiocytosis: A single-center analysis
- CXCL-9 and IL-18: Potential Biomarkers for Efficacy Evaluation in Refractory Hemophagocytic Lymphohistiocytosis Treated with RED (Ruxolitinib, Emapalumab and Dexamethasone)
- Rovadicitinib in Patients with Hemophagocytic Lymphohistiocytosis: A Single Arm, Open-Label, Phase I Study
- Zanubrutinib As Salvage Therapy for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis in Adults: A Single Center, Prospective Study
- Caebv Disease Originates from Infected Hematopoietic Stem Cells
- Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society
- P9.40: Liver Transplantation for Secondary Hemophagocytic Lymphohistiocytosis Associated Acute Liver Failure: A Case Report
血液疾病
血友病 A
Haemophilia A2021–2025 年没有牵头血友病 A的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 15 家医院列在血友病 A下全国有 160 家医院列在血友病 A下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Longitudinal Cohort of Thrombosis and Hemostasis Diseases
- 分期
- 未注明
- 开始
- 2024-11
- 登记号
- NCT06727669
年龄未注明(登记的条件)
牵头:北京大学人民医院;另有 4 家列出的医院为研究中心北京、郑州、重庆
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
血液疾病
血栓性血小板减少性紫癜
Thrombotic thrombocytopenic purpura2021–2025 年没有牵头血栓性血小板减少性紫癜的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 8 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Longitudinal Cohort of Thrombosis and Hemostasis Diseases
- 分期
- 未注明
- 开始
- 2024-11
- 登记号
- NCT06727669
年龄未注明(登记的条件)
牵头:北京大学人民医院;另有 4 家列出的医院为研究中心北京、郑州、重庆
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
IgG4相关性疾病
IgG4-related disease2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 12 篇,占 4.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 11 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
- 分期
- I/II期
- 开始
- 2026-01
- 登记号
- NCT07061938
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、成都、武汉
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文12
- Does adjunctive endoscopic biliary drainage improve outcomes beyond glucocorticoids alone in IgG4-related pancreatobiliary disease?
- Correlations between IgG4-related disease and allergic reactions: implications for future therapeutic strategies.
- Animal models of IgG4-related disease.
- Risk factors for relapse of IgG4-related disease: a systematic review and meta‑analysis.
- Diagnostic value of a novel salivary gland ultrasound scoring system in IgG4-related sialadenitis.
- Systematic analysis for clinical characteristics and outcomes of IgG4-related disease patients during the COVID-19 pandemic.
- Performance of the 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease in a Large Chinese Cohort.
- Three cases of IgG4-RD complicated by splenic artery aneurysm: a complication of IgG4-RD?
- Association Between Immunoglobulin G4-Related Ophthalmic Disease and Nonlymphoid Malignancy Case Series and Comprehensive Review of the Literature.
- Clinical characteristics of IgG4-related respiratory disease patients: a large Chinese cohort study.
- Clinical characteristics and therapeutic response of immunoglobulin G4-related disease: a retrospective study of 127 Chinese patients.
- The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 11 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。
其他疾病
肝豆状核变性
Wilson disease2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 4 篇,占 2.0%。
北京有 3 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募China Registry for Genetic / Metabolic Liver Diseases
- 分期
- 未注明
- 开始
- 2015-06
- 登记号
- NCT03131427
年龄未注明(登记的条件)
牵头:首都医科大学附属北京友谊医院;另有 1 家列出的医院为研究中心北京
- 正在招募Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
- 分期
- III期
- 开始
- 2026-09
- 登记号
- NCT07465718
年龄 8 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、杭州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文4
- Dysfunction of ATP7B Splicing Variant Caused by Enhanced Interaction With COMMD1 in Wilson Disease.
- Hepatic progenitor cells reprogrammed from mouse fibroblasts repopulate hepatocytes in Wilson's disease mice.
- Laboratory and clinical evaluation of a microarray for the detection of ATP7B mutations in Wilson disease in China.
- Identification of potential modifier genes in Chinese patients with Wilson disease.
中文论文(未计入)3
其他疾病
胆道闭锁
Biliary atresia2021–2025 年中国大陆作者发表的 214 篇胆道闭锁 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 3 家医院列在胆道闭锁下全国有 28 家医院列在胆道闭锁下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胆道闭锁开放试验。
这些数字背后的记录
牵头的论文4
- Ocular Involvement in Post-Transplantation Lymphoproliferative Disorder: A Rare Case with Rituximab Hypersensitivity.
- Short limb in biliary tract reconstruction: A retrospective study of living donor liver transplantation in children with biliary atresia.
- Association of Gut Microbiota and Metabolites With Disease Progression in Children With Biliary Atresia.
- Post-transplant Lymphoproliferative Disorder in Recipient's Reconstructed Middle Hepatic Vein After Pediatric Living Donor Liver Transplant: A Case Report.
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 30 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
这些数字背后的记录
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 27 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- 分期
- III期
- 开始
- 2026-09
- 登记号
- NCT07687459
年龄 40 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
其他疾病
庞贝病
Pompe disease2021–2025 年中国大陆作者发表的 30 篇庞贝病 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 6 家医院列在庞贝病下全国有 30 家医院列在庞贝病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的庞贝病开放试验。
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 24 家医院列在白塞病下全国有 149 家医院列在白塞病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- 分期
- III期
- 开始
- 2023-11
- 登记号
- NCT06145893
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 32 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
其他疾病
戈谢病
Gaucher disease2021–2025 年中国大陆作者发表的 30 篇戈谢病 PubMed 英文论文中,这家医院牵头了 2 篇,占 6.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 5 家医院列在戈谢病下全国有 41 家医院列在戈谢病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的戈谢病开放试验。
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 12 篇,占 4.0%。
北京有 16 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募PBC Long-term Outcomes Study
- 分期
- 未注明
- 开始
- 2025-05
- 登记号
- NCT07149675
年龄未注明(登记的条件)
牵头:首都医科大学附属北京友谊医院北京
- 正在招募A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- 分期
- III期
- 开始
- 2025-12
- 登记号
- NCT07282353
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 35 家列出的医院为研究中心Baoji、上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- 分期
- III期
- 开始
- 2023-09
- 登记号
- NCT06051617
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文12
- Autoimmune liver diseases in the Asia Pacific region: proceedings of the autoimmune liver disease course at APASL 2025.
- Double-negative T cells in combination with ursodeoxycholic acid ameliorates immune-mediated cholangitis in mice.
- GLOBE Score and UK-PBC Risk Score Predict Long-Term Clinical Outcomes of Patients With Primary Biliary Cholangitis and Receiving Ursodeoxycholic Acid and Fenofibrate.
- Clinicopathologic Features of a Rare and Underrecognized Variant of Early-stage Primary Biliary Cholangitis With Ductopenia.
- Primary Biliary Cholangitis Associated with Ulcerative Colitis: Case Series and Literature Review.
- Obliteration of portal venules contributes to portal hypertension in biliary cirrhosis.
- Concomitant gallstone disease was not associated with long-term outcomes in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
- Concomitant extrahepatic autoimmune diseases do not compromise the long-term outcomes of primary biliary cholangitis.
- APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.
- Reciprocal alterations in circulating and hepatic gamma-delta T cells in patients with primary biliary cholangitis.
- Rare liver diseases are not rare in China.
- Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.
中文论文(未计入)3
- [Research progress on early-stage primary biliary cholangitis accompanied by portal hypertension].
- [Clinical features and long-term prognosis of primary biliary cholangitis in patients with past hepatitis B virus infection].
- [Recommendations of APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis].
早期论文(2016–2020 年)10
- Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis.
- Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China.
- Alteration of liver-infiltrated and peripheral blood double-negative T-cells in primary biliary cholangitis.
- Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
- A brief review on prognostic models of primary biliary cholangitis.
- [Risk factors and therapeutic strategies for primary biliary cholangitis patients with poor prognosis].
- [Research advances in primary biliary cholangitis].
- Optimal Adaptive Statistical Iterative Reconstruction Percentage in Dual-energy Monochromatic CT Portal Venography.
- Quantitative fibrosis parameters highly predict esophageal-gastro varices in primary biliary cirrhosis.
- Dual Energy CT (DECT) Monochromatic Imaging: Added Value of Adaptive Statistical Iterative Reconstructions (ASIR) in Portal Venography.
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- PBC Long-term Outcomes Study
- Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
- Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis
- Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 4 篇,占 4.0%。
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 10 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
- 分期
- III期
- 开始
- 2026-05
- 登记号
- NCT07387549
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、天津、广州、济南、郑州、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文4
- Autoimmune liver diseases in the Asia Pacific region: proceedings of the autoimmune liver disease course at APASL 2025.
- MRI findings of confluent hepatic fibrosis caused by different etiologies.
- Prevalence and clinical profiles of primary sclerosing cholangitis in China: Data from electronic medical records and systematic literature retrieval.
- Rare liver diseases are not rare in China.
中文论文(未计入)2
其他疾病
先天性巨结肠
Hirschsprung disease2021–2025 年没有牵头先天性巨结肠的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 8 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。
其他相关研究
联系这家医院
出示给工作人员或司机的院名卡
首都医科大学附属北京友谊医院
Beijing Friendship Hospital
北京
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR
Capital Medical University Affiliated Beijing Friendship Hospital; Beijing Friendship Hospital Affiliated to Capital Medical University; Beijing Friendship Hospital of Capital Medical University; Beijing friendship hospital; Beijing Friendship Hospital Cancer Center; Beijing Friendship Hospita; Library of Beijing Friendship Hospital; Beijing Friendship Hospital of the Capital Medical University